Wire · operational-macro
FDA approves stroke prevention drug promising major potential
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
The FDA has approved Bayer's asundexian, branded Sunharbo, as a stroke prevention drug for patients with mild-to-moderate non-cardio-embolic ischaemic stroke or high-risk transient ischaemic attack, marking the first approval of a factor XIa inhibitor with a list price of $748.50 for a 30-day supply and potential peak sales of $3.4bn.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
The FDA approval opens a lucrative market for stroke prevention therapies, signalling a chance for you to engage with new treatment protocols and partnerships in cardiovascular care.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics